AGAM
DFTX

Audent Global Asset Management’s Definium Therapeutics DFTX Stock Holding History

Audent Global Asset Management’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$245K Buy
+5,200
New +$128K 0.27% 43
2022
Q3 		– Sell
-5,200
Closed -$50K – 47
2022
Q2 		$50K Hold
5,200
– – 0.03% 45
2022
Q1 		$87K Hold
5,200
– – 0.05% 48
2021
Q4 		$108K Buy
+5,200
New +$166K 0.05% 46

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Audent Global Asset Management's DFTX Position: Q2 2026 in Review

Audent Global Asset Management opened a new position in Definium Therapeutics (DFTX) in Q2 2026: 5,200 shares worth $245K. The stake represents 0.27% of the portfolio and ranks #43 among its holdings. This is a return to the name: Audent Global Asset Management previously reported a position in DFTX as recently as Q2 2022.

Audent Global Asset Management first reported a position in DFTX in Q4 2021 and has held it in 4 quarters since. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Audent Global Asset Management held 5,200 shares of Definium Therapeutics worth $245K as of Q2 2026.
  • Definium Therapeutics was a new Audent Global Asset Management position in Q2 2026.
  • Definium Therapeutics made up 0.27% of Audent Global Asset Management's portfolio in Q2 2026, its #43 holding.
  • Audent Global Asset Management first reported a position in Definium Therapeutics in Q4 2021 and has held it in 4 quarters since.
  • 362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Audent Global Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.